» Authors » Jose L Miguel-Carrasco

Jose L Miguel-Carrasco

Explore the profile of Jose L Miguel-Carrasco including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 236
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Blanca A, Ruiz-Armenta M, Zambrano S, Miguel-Carrasco J, Gonzalez-Roncero F, Fortuno A, et al.
Food Chem . 2017 Mar; 228:356-366. PMID: 28317735
l-Carnitine (LC) exerts beneficial effects in arterial hypertension due, in part, to its antioxidant capacity. We investigated the signalling pathways involved in the effect of LC on angiotensin II (Ang...
2.
Blanca A, Ruiz-Armenta M, Zambrano S, Salsoso R, Miguel-Carrasco J, Fortuno A, et al.
J Cell Biochem . 2016 Feb; 117(10):2281-8. PMID: 26918530
Leptin is a protein involved in the regulation of food intake and in the immune and inflammatory responses, among other functions. Evidences demonstrate that obesity is directly associated with high...
3.
Blanca A, Ruiz-Armenta M, Zambrano S, Miguel-Carrasco J, Arias J, Arevalo M, et al.
Toxicol Lett . 2015 Nov; 241:9-18. PMID: 26581635
Sunitinib (Su) is currently approved for treatment of several malignances. However, along with the benefits of disease stabilization, cardiovascular toxicities have also been increasingly recognized. The aim of this study...
4.
Zambrano S, Blanca A, Ruiz-Armenta M, Miguel-Carrasco J, Arevalo M, Mate A, et al.
Am J Hypertens . 2014 Jan; 27(3):460-70. PMID: 24413708
Background: The development of renal fibrosis is a consequence of arterial hypertension. L-carnitine plays an essential role in the β-oxidation of fatty acids, and we have previously demonstrated hypotensive, antioxidant,...
5.
Zambrano S, Blanca A, Ruiz-Armenta M, Miguel-Carrasco J, Arevalo M, Vazquez M, et al.
Biochem Pharmacol . 2013 Jan; 85(7):937-44. PMID: 23295156
Cardiac fibrosis is a pathogenic factor in a variety of cardiovascular diseases and is characterized by an abnormal accumulation of extracellular matrix protein that leads to cardiac dysfunction. l-Carnitine (LC)...
6.
Mate A, Miguel-Carrasco J, Monserrat M, Vazquez C
J Physiol Biochem . 2010 May; 66(2):127-36. PMID: 20506010
In spite of a wide range of drugs being available in the market, treatment of arterial hypertension still remains a challenge, and new therapeutic strategies could be developed in order...
7.
Miguel-Carrasco J, Zambrano S, Blanca A, Mate A, Vazquez C
J Inflamm (Lond) . 2010 May; 7:21. PMID: 20462420
Background: Captopril is an angiotensin-converting enzyme (ACE) inhibitor widely used in the treatment of arterial hypertension and cardiovascular diseases. Our objective was to study whether captopril is able to attenuate...
8.
Mate A, Miguel-Carrasco J, Vazquez C
Drug Discov Today . 2010 Apr; 15(11-12):484-92. PMID: 20363359
Subclinical organ damage is a very important aspect when assessing total cardiovascular risk in hypertensive subjects. Therapeutic strategies in those patients should consider treatment of hypertension-related cardiovascular and renal damage...
9.
Miguel-Carrasco J, Monserrat M, Mate A, Vazquez C
Eur J Pharmacol . 2010 Feb; 632(1-3):65-72. PMID: 20123095
It has been shown that oxidative stress is involved in the pathogenesis of arterial hypertension. The aim of this work was to study and compare the molecular mechanisms of the...
10.
Miguel-Carrasco J, Mate A, Monserrat M, Arias J, Aramburu O, Vazquez C
Am J Hypertens . 2008 Sep; 21(11):1231-7. PMID: 18787523
Background: The mechanism(s) underlying the effects of L-carnitine (beta-hydroxy-gamma-N-trimethylammonium-butyrate; LC) in cardiovascular diseases are not well clarified. Previous studies have demonstrated that oxidative stress and inflammation contribute to arterial hypertension,...